Dazodalibep
Two Phase 3 studies in Sjögren's disease are expected to finish in H2 2026.
What it is
Investigational treatment for Sjögren's disease, a chronic autoimmune condition that affects salivary and tear glands. It is in Phase 3 testing with no approval yet.
Why it matters to the stock. Dazodalibep could be Amgen's next new immunology product. The two Phase 3 results set the timing of any filing.
News
Dazodalibep meets primary endpoint in first Phase 3 study in systemic Sjogren's disease
Amgen reported positive topline results on September 22, 2026 from OASIZ 301, a Phase 3 study of dazodalibep in moderate-to-severe systemic Sjogren's disease.
Project